Profile
Sector:
Real EstateIndustry:
ServicesCountry:
United StatesIPO:
27 March 2018Website:
http://www.rafaelholdings.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Mon, 04 Nov 2024 21:00:02 GMTDividend
Analysts recommendations
Institutional Ownership
RFL Latest News
Company continues to take additional and enhanced actions to harden the grid as part of the Greater Houston Resiliency Initiative CenterPoint encourages customers to remain vigilant and have a plan for extreme weather HOUSTON , Nov. 4, 2024 /PRNewswire/ -- While fall is in full swing in many parts of the United States, CenterPoint Energy has been monitoring tropical developments over the weekend and is activating its emergency response plans. It is also making early preparations for any potential tropical storm or hurricane threats for this coming weekend.
DALLAS , Aug. 26, 2024 /PRNewswire/ -- Texas Instruments Incorporated (TI) (Nasdaq: TXN) Senior Vice President and Chief Financial Officer Rafael Lizardi will speak at the Goldman Sachs 2024 Communacopia + Technology Conference in San Francisco on Tuesday, Sept. 10, at 10:10 a.m.
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential
What type of business is Rafael Holdings?
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
What sector is Rafael Holdings in?
Rafael Holdings is in the Real Estate sector
What industry is Rafael Holdings in?
Rafael Holdings is in the Services industry
What country is Rafael Holdings from?
Rafael Holdings is headquartered in United States
When did Rafael Holdings go public?
Rafael Holdings initial public offering (IPO) was on 27 March 2018
What is Rafael Holdings website?
https://www.rafaelholdings.com
Is Rafael Holdings in the S&P 500?
No, Rafael Holdings is not included in the S&P 500 index
Is Rafael Holdings in the NASDAQ 100?
No, Rafael Holdings is not included in the NASDAQ 100 index
Is Rafael Holdings in the Dow Jones?
No, Rafael Holdings is not included in the Dow Jones index
When was Rafael Holdings the previous earnings report?
No data
When does Rafael Holdings earnings report?
Next earnings report date is not announced yet